Market revenue in 2022 | USD 12.7 million |
Market revenue in 2030 | USD 34.0 million |
Growth rate | 13.1% (CAGR from 2022 to 2030) |
Largest segment | Cholinesterase inhibitors |
Fastest growing segment | Combination Drugs |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cholinesterase inhibitors, NMDA Receptor Antagonist, Combination Drugs |
Key market players worldwide | Eisai Co Ltd, Novartis AG ADR, AbbVie Inc, H. Lundbeck AS Class A, Biogen Inc, Roche Holding AG ADR, Daiichi Sankyo Co Ltd, Johnson & Johnson, AC Immune SA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to alzheimers therapeutics market will help companies and investors design strategic landscapes.
Cholinesterase inhibitors was the largest segment with a revenue share of 52.76% in 2022. Horizon Databook has segmented the South Africa alzheimers therapeutics market based on cholinesterase inhibitors, nmda receptor antagonist, combination drugs covering the revenue growth of each sub-segment from 2018 to 2030.
South Africa is the largest market for Alzheimer’s therapeutics in the African continent. Increasing geriatric population and rising awareness about Alzheimer’s in the country are driving treatment rate among the people living with AD.
Around 750,000 people in South Africa are living with dementia. However, awareness about Alzheimer’s is limited in the country. Hence, to raise awareness, some organizations such as Alzheimer’s South Africa are focusing on reducing the risk and prevalence of this disease.
These organizations create public awareness and support by providing education & training programs to the people. South African government is working to improve access to effective medical treatments. The country has introduced price control measures such as capped annual price of expensive drugs.
Horizon Databook provides a detailed overview of country-level data and insights on the South Africa alzheimers therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into South Africa alzheimers therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account